| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
Purity: ≥98%
| Targets |
SU 4942 is a modulator of tyrosine kinase signaling. It inhibits endothelial cell mitogenesis induced by Vascular Endothelial Growth Factor (VEGF) and Endothelial Cell Growth Factor (ECGF). By inhibiting these growth factor-induced signaling pathways, SU 4942 modulates angiogenesis and endothelial cell proliferation. The compound's mechanism of action involves the inhibition of tyrosine kinase signaling pathways that are activated by VEGF and ECGF.
|
|---|---|
| ln Vitro |
In vitro, SU 4942 inhibits VEGF- and endothelial cell growth factor (ECGF)-induced mitogenesis in endothelial cells. It also inhibits VEGF- or acidic FGF-induced mitogenesis of endothelial cells. Its in vitro activity is characterized by potent inhibition of growth factor-induced endothelial cell proliferation. SU 4942 is used as a research tool to study angiogenesis and tyrosine kinase signaling.
|
| ln Vivo |
In vivo, SU 4942 has shown promise in preclinical models for its anti-tumor and anti-angiogenic effects. As a modulator of tyrosine kinase signaling, it may inhibit angiogenesis and tumor growth. However, detailed in vivo efficacy data for specific disease models are limited in the available literature. SU 4942 is primarily used as a research tool for studying angiogenesis and tyrosine kinase biology.
|
| Enzyme Assay |
In vitro enzyme assays for SU 4942 typically involve measuring the inhibition of tyrosine kinase signaling pathways. The compound inhibits VEGF- and ECGF-induced mitogenesis in endothelial cells. These assays confirm the compound's mechanism of action as a modulator of tyrosine kinase signaling.
|
| Cell Assay |
In vitro cellular assays for SU 4942 typically involve treating endothelial cells with the compound and measuring mitogenesis induced by VEGF or ECGF. The compound inhibits VEGF- and ECGF-induced mitogenesis. These cell-based studies demonstrate the compound's functional inhibition of growth factor-induced endothelial cell proliferation.
|
| Animal Protocol |
In vivo animal models for SU 4942 may include xenograft tumor models or angiogenesis models to evaluate its anti-tumor and anti-angiogenic effects. The compound is administered by appropriate routes, and tumor growth or angiogenesis is assessed. However, detailed animal protocol information for SU 4942 is limited in the available literature. The compound is primarily used as a research tool.
|
| ADME/Pharmacokinetics |
SU 4942 has a molecular weight of 300.15 g/mol. The compound is typically stored under appropriate conditions to maintain stability. Its physicochemical properties support its use in both in vitro and in vivo studies. SU 4942's solubility and formulation for administration should be optimized based on specific experimental requirements. The compound is a tyrosine kinase signaling modulator.
|
| Toxicity/Toxicokinetics |
SU 4942 is a tyrosine kinase signaling modulator with a well-characterized mechanism of action. As with any kinase modulator, potential toxicity may include off-target effects on other signaling pathways. The compound's safety profile should be evaluated in preclinical toxicology studies. SU 4942 is for research use only and is not approved for human therapeutic use. It represents a valuable tool for studying angiogenesis and tyrosine kinase signaling.
|
| References |
: Cohen AJ, Packiam VT, Nottingham CU, Alberts BD, Faris SF, Bales GT. 30-Day Morbidity and Reoperation Following Midurethral Sling: Analysis of 8772 Cases Using a National Prospective Database. Urology. 2016 Sep;95:72-9. doi: 10.1016/j.urology.2016.04.043. PubMed PMID: 27196030.
|
| Additional Infomation |
SU 4942 (CAS# 76086-99-2) is a tyrosine kinase signaling modulator. It inhibits VEGF- and endothelial cell growth factor (ECGF)-induced mitogenesis in endothelial cells. SU 4942 functions as a modulator of tyrosine kinase signaling, specifically inhibiting endothelial cell mitogenesis induced by VEGF and ECGF. It has shown promise in preclinical models for its anti-tumor and anti-angiogenic effects. The compound is for research use only and is not approved for human therapeutic use.
|
| Molecular Formula |
C15H10BRNO
|
|---|---|
| Molecular Weight |
300.155
|
| Exact Mass |
298.995
|
| CAS # |
76086-99-2
|
| Related CAS # |
76086-99-2;
|
| PubChem CID |
964113
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
4.079
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
18
|
| Complexity |
358
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C2C(=C1)/C(=C/C3=CC=C(C=C3)Br)/C(=O)N2
|
| InChi Key |
INAOSTJXLBNFMV-LCYFTJDESA-N
|
| InChi Code |
InChI=1S/C15H10BrNO/c16-11-7-5-10(6-8-11)9-13-12-3-1-2-4-14(12)17-15(13)18/h1-9H,(H,17,18)/b13-9-
|
| Chemical Name |
3-(4-Bromobenzylidene)-1,3-dihydroindol-2-one
|
| Synonyms |
SU 4942 SU-4942 SU4942.
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~832.92 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.93 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3316 mL | 16.6578 mL | 33.3156 mL | |
| 5 mM | 0.6663 mL | 3.3316 mL | 6.6631 mL | |
| 10 mM | 0.3332 mL | 1.6658 mL | 3.3316 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA